BioAge Labs GAAP EPS of -$0.73 misses by $0.09, revenue of $0.3M misses by $1.18M

BioAge Labs reported Q3 GAAP EPS of -$0.73, missing estimates by $0.09. Revenue was $0.3M, down 85.7% year-over-year, and missed expectations by $1.18M. The company had $352.3M in cash and equivalents as of September 30, 2026.

Original reporting
Published Nov 6, 2026, 5:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BIOA
Bearish
high confidence
Mentioned
$BIOA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BIOABearishMed
01

Why it matters

The earnings miss may prompt short sellers and could lead to a price decline in the near term.

02

Market read

Microcap biotech earnings miss with limited broader market impact.

03

What to watch

Potential upcoming clinical trial milestones not mentioned in the release.

Relevance 6/10Novelty 7/10Timing: after-hours release

Background

BioAge Labs reported its Q3 2026 GAAP earnings, showing a significant revenue decline and an EPS miss.

Company-level read

Ticker impact

$BIOABearishHigh confidence
Context

Q3 GAAP EPS of -$0.73 missed expectations and revenue of $0.3M fell 85.7% YoY, a fresh earnings miss disclosed for the first time.

Expected impact

downward pressure as the market prices in the earnings miss

Evidence & confidence

Both EPS and revenue came in below expectations, and the company has a small cash base, suggesting limited upside.

Market effects

Limited impact on the broader biotech sector due to the company's small size.

Negligible effect on US markets overall.

Minimal global relevance.

Counterpoint

The miss may be temporary; cash runway could support a rebound if upcoming pipeline data are positive.

Key entities

  • BioAge Labs, Inc.

    Biotech firm reporting Q3 earnings.

Related articles

$BIOAMedAI 8/10

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMed

BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.

$BIOAMed

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

$BIOAMed

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.